CORE LABORATORIES ($CLB) posted quarterly earnings results on Wednesday, July 23rd. The company reported earnings of $0.19 per share, missing estimates of $0.19 by $0.00. The company also reported revenue of $130,160,000, beating estimates of $130,128,905 by $31,095.
You can see Quiver Quantitative's $CLB stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
CORE LABORATORIES Hedge Fund Activity
We have seen 75 institutional investors add shares of CORE LABORATORIES stock to their portfolio, and 109 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARIEL INVESTMENTS, LLC added 709,455 shares (+7.4%) to their portfolio in Q1 2025, for an estimated $10,634,730
- BLACKROCK, INC. removed 412,761 shares (-5.2%) from their portfolio in Q1 2025, for an estimated $6,187,287
- HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC added 400,790 shares (+inf%) to their portfolio in Q1 2025, for an estimated $6,007,842
- MORGAN STANLEY removed 305,193 shares (-34.1%) from their portfolio in Q1 2025, for an estimated $4,574,843
- RAYMOND JAMES FINANCIAL INC removed 196,652 shares (-50.4%) from their portfolio in Q1 2025, for an estimated $2,947,813
- FRED ALGER MANAGEMENT, LLC added 180,344 shares (+32.4%) to their portfolio in Q1 2025, for an estimated $2,703,356
- VANGUARD GROUP INC removed 174,600 shares (-3.1%) from their portfolio in Q1 2025, for an estimated $2,617,254
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
CORE LABORATORIES Price Targets
Multiple analysts have issued price targets for $CLB recently. We have seen 2 analysts offer price targets for $CLB in the last 6 months, with a median target of $12.5.
Here are some recent targets:
- Stephen Gengaro from Stifel set a target price of $12.0 on 07/16/2025
- Scott Gruber from Citigroup set a target price of $13.0 on 05/13/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
